NCT06265883
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
Clinical trial condition
Hepatocellular Carcinoma Non-resectable
Explore clinical trials studying Hepatocellular Carcinoma Non-resectable. Study availability and eligibility vary by location and protocol.
42 public trials
17 recruiting studies
Hepatocellular Carcinoma Non-resectable trial results
NCT04599790
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Locations
-
- The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
NCT03379844
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Erasmus Medical Center Rotterdam, Netherlands
- University Medical Center Utrecht Utrecht, Netherlands
NCT04599777
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Locations
-
- The 2nd Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
- the Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
NCT04966195
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more
- Locations
-
- the second affiliated hospital of Zhejiang University Hangzhou, Zhejiang, China
Completed
Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma
NCT03138031
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Locations
-
- Ribat University Hospital Khartoum, Sudan
NCT03533920
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Locations
-
- Chonnam National University Hospital Gwangju, South Korea
- Seoul National University Bundang Hospital Gyeonggi-do, South Korea
- The Catholic University of Korea, Uijeongbu ST. Mary's Hospital Gyeonggi-do, South Korea
- Inha University Hospital Incheon, South Korea
NCT03564405
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Locations
-
- Catholic University Seoul St. Mary Hospital Seoul, South Korea
Active, Not Recruiting
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
NCT06187961
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
Active, Not Recruiting
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
NCT04522544
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Universitätsklinikum Bonn Bonn, Germany
- Universitätsklinikum Köln Cologne, Germany
- Universitätsklinikum Essen Essen, Germany
- Universitätsmedizin Göttingen Göttingen, Germany